CRISPR Effector Diagnostics for Portable Single-Base Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid detection methods face trade-offs among sensitivity, specificity, simplicity, and speed, limiting their usability in both clinical and basic research settings.
Innovation Solution
A CRISPR-based nucleic acid detection system utilizing an effector protein, guide RNAs, and RNA-based masking constructs, optionally with nucleic acid amplification reagents, to enhance sensitivity and specificity on a portable platform.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If qPCR approaches are used for nucleic acid detection, then sensitivity is improved, but device complexity and cost increase due to complex instrumentation requirements
Solution Approach 1:
The patent replaces complex mechanical/optical instrumentation (qPCR machines) with a biochemical system using CRISPR-Cas12a effector protein that produces detectable signals through specific molecular interactions. The system uses simple colorimetric or fluorescent readouts that can be measured with basic equipment, eliminating the need for sophisticated thermal cyclers and real-time detection systems while maintaining high sensitivity through the programmable specificity of guide RNAs.
Solution Approach 2:
The patent introduces an intermediary CRISPR-Cas12a system that bridges target nucleic acid detection and signal generation. The guide RNA acts as a mediator that specifically recognizes the target sequence, activating Cas12a to produce detectable signals. This intermediary layer provides both the sensitivity and specificity of complex methods while using simpler detection chemistry.
2Device complexity
If isothermal nucleic acid amplification with portable platforms is used, then device complexity is reduced for point-of-care use, but detection sensitivity decreases
Solution Approach 1:
The patent merges isothermal amplification (RPA or LAMP) with CRISPR-Cas12a detection in a single integrated system. The amplification reagents and CRISPR components are combined in one reaction mixture, allowing simultaneous amplification and detection in a portable format. This merging maintains sensitivity by ensuring that amplified products are immediately detected by the highly sensitive CRISPR system, while keeping the device simple and portable.
3Ease of operation
If conventional detection methods are used, then ease of operation is maintained, but manufacturing precision and single-base specificity are insufficient
Solution Approach 1:
The patent changes the recognition parameter from conventional probe hybridization to CRISPR guide RNA-programmed recognition, which provides single-base specificity through the precise Watson-Crick base pairing of the guide RNA with the target. The system maintains ease of operation by using simple colorimetric or fluorescent readouts that can be detected with basic equipment, while achieving high precision through the programmable nature of guide RNAs that can be designed to match any target sequence with single-nucleotide discrimination.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves high sensitivity and specificity in detecting nucleic acids, enabling rapid diagnostics for various diseases and conditions, including cancer and infections, with potential applications in point-of-care settings.
Implementation Method 1
a CRISPR system comprising an effector protein and one or more guide RNAs designed to bind to corresponding target molecules
Implementation Method 2
nucleic acid amplification reagents to amplify target RNA molecules in a sample
Data Source
AI summary
The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect broth DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.